 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Stewardship Prompts to Improve Antibiotic Selection  
for Urinary Tract Infection: The I NSPI[INVESTIGATOR_341062]# : 03697096  
 
7/3/2018 
INSPI[INVESTIGATOR_21392]  (INtelligent  Stewardship Prompts  to Improve  Real-time Empi[INVESTIGATOR_341063] (UTI) ): The INSPI[INVESTIGATOR_21392] -ASP UTI Trial  Protocol  
 
A. Background and Goals  
A.1.[ADDRESS_422207] infection (UTI).1 In treating these infections , the Ce nters for Disease Control and 
Prevention (CDC) has found that antibiotic prescribing could be improved in 35- 40% of patients.[ADDRESS_422208] ~[ADDRESS_422209] fueled 
national calls to improve antibiotic choices by [CONTACT_341142].8-13 There is a 2020 target to 
reduce ‚Äúinappropriate‚Äù antibiotic prescribing in hospi[INVESTIGATOR_341064] 20%, as discussed in the 2014 ‚ÄúNational 
Strategy f or Comba ting Antibiotic -Resistant Bacteria‚Äù released by [CONTACT_341143].[ADDRESS_422210] practices for improving judicious anti biotic p rescribing. Evidence, engagement, 
and education are required to build a culture where it is accepted that rationale antibiotic 
prescribing is every physician‚Äôs responsibility.[ADDRESS_422211] empi[INVESTIGATOR_341065] a patient‚Äôs condition, selecting the wrong dose or du ration, and failing to re- evaluate the choices that 
have been made. Empi[INVESTIGATOR_341066]. We focus here on improving the empi[INVESTIGATOR_341067] d patients that have an appropriate indication.  
When selecting initial antibiotics for common community -acquired conditions that cause 
admission, such as pneumonia and urinary tract infection (U TI), physicians vary widely in their 
adherence to nati onal gui delines.
18-20 This is often due to misperceptions that multidrug -resistant 
organisms (MDROs) are more common than they actually are, or beliefs that extended- spectrum 
antibiotics are more effect ive in curing infections than standard -spectrum choices, even for 
pathogens sensitive to standard- spectrum agents.21 Often, such perceptions are based on studies 
on critically ill patients and those with infections caused by [CONTACT_115959]- resistant Staphyloc occus 
aureus (MRSA), Pseudomonas aeruginosa, and extended- spec trum beta -lactamase producing 
(ESBL) Enterobacteriaceae.22-[ADDRESS_422212] been called ‚Äúthe missing care 
bundle,‚Äù[ADDRESS_422213] to 
extrapolate the probability that the in fection is due to a particular pathogen. As mentioned above, 
physicians are expected to use local antibiogram data from their microbiology laboratory to determine the risk of an MDRO infection in a give n patient.
51-54,92 Yet, these data are not presented 
in a manner helpful to clinical decision -making.93 For example, national data shows that over 50% 
of S. aureus  are resistant to methicillin (MRSA), and 22% of E. coli  and 30% of P. aeruginosa are 
resista nt to fluoroquinolones.94 
These data may be misinterpr eted as the probability that a patient has an MDRO infection. 
However, when accounting for the likelihood that a patient is infected with these pathogens, the risk 
of MDRO infection drops substantially.  In two recent studies of patients presenting from the 
communi ty with pneumonia, there was a 2.5- 4.6% risk of MRSA, a 1.0- 1.9% risk of Gram -negative 
Enterobacteriaceae , and a 0.7- 1.2% risk of P. aeruginosa resistant to standard- spectrum 
antibiotics.26,94 -95   
Instead of providing the MDRO risk by [CONTACT_209058], physicians would be better served by 
[CONTACT_341144]. Though precision 
medicine tools in antibiotic stewardship are lacking, there i s evidence that precision medicine 
approaches can subs tantially improve patient care.56-59 This involves reformulating a hospi[INVESTIGATOR_600]‚Äô 
antibiogram data into disease- specific probabilities of MDRO infection to facilitate appropriate 
prescribing.  
A.1.[ADDRESS_422214] generation cephalosporin such as ceftriaxone as empi[INVESTIGATOR_341068] .18-20 There i s growin g 
evidence that fluoroquinolones are associated with serious adverse drug reactions and an increased risk of C. difficile colitis.
99-101 The Food and Drug Administration (FDA) has also issued a 
warning ( May, 2016) against the routine use of fluoroquinolones, particularly for conditions in which 
resistance is known to be high, such as urinary tract infection .102,[ADDRESS_422215] been shown 
to increase a patient‚Äôs risk for future MDRO, length of stay, risk for C. difficile  colitis, healthc are 
costs, and mortality.99,103  Data are emerging that there is time to await definitive culture data to 
inform antibiotic treatment and that a delay in antibiotics targeting resistant organisms is not 
necessarily harmful and may improve outcomes.103-105    
 
B. INSPI[INVESTIGATOR_21392] -ASP UTI Trial Study Design  & Population  
 
B.1.1 INSPI[INVESTIGATOR_21392] -ASP UTI Trial Study Design & Population  
The INSPI[INVESTIGATOR_21392] -ASP Trial is  a two -arm cluster -randomized trial in HCA hospi[INVESTIGATOR_341069] -
of-care precision medicine computerized physician order entry (CP OE) smart prompt  for adult 
patients admitted to general medical or surgical floors . The unit of randomization will be the 
hospi[INVESTIGATOR_307]. The trial will begin with a six -month phase- in period from Oc tober 1, [ADDRESS_422216] 3 days of hospi[INVESTIGATOR_059]. A baseline period between April 1, 2017 -September 30, 2018 will be utiliz ed for comparison with the interv ention period at each  
hospi[INVESTIGATOR_307]. Per guidance from  the Office for Human Research Protections (OHRP) , prisoners will not 
be included in this t rial. P rescribers and antibiotic stewardship teams in intervention facilities will be 
trained (e.g., coaching calls,  usual communication channels (email, flyers)) that prisoners should be 
excluded from the t rial (i.e., the CPOE smart prompt should not be acted upon for these 
individuals). D ata for any prisoners that may be inadvertently included in study datasets will be  
removed prior to analyses using claims data as well as admission/discharge/transfer codes 
indicating ‚ÄòCourt/Law Enforcement‚Äô . 
 
B.1.2 HCA Healthcare Infrastructure for the INSPI[INVESTIGATOR_21392] -ASP Intervention Arm  
HCA Healthcare curren tly requires physicians to provide  an indication when an antibiotic is 
ordered (see Appendix B for example CPOE indication screens ). For facilities assigned to the 
intervention arm of the INSPI[INVESTIGATOR_21392] -ASP Trial,  an INSPI[INVESTIGATOR_341070] d-spectrum (ES, Table 1) for a UTI indication in the first three days 
of a hospi[INVESTIGATOR_4408]. This CPOE smart prompt  will provide clinicians with a patient -specific estimate of 
the likelihood that the UTI is due to the associated target pathogens (e.g. MRSA,  VRE, 
Pseudomonas, ESB L, or CRE, Table  1). The smart prompt will also provide guidance for  
appropriate empi[INVESTIGATOR_341071] .   
For example, if an anti -Pseudomonas  antibiotic is being ordered for UTI, the clinicia n will 
receive a prom pt during the ordering process  providing the probabili ty that the patient has UTI due 
to Pseudomonas aeruginosa. R ecommendations for  using standard- spectrum antibiotics (e.g. 
ceftriaxone) will be made w hen the probability of a given M DRO is lower than a gi ven threshold 
(e.g., <10%). This threshold used in the trial will be finalized after evaluation of the prevalence of 
MDROs, and after discussion with the INSPI[INVESTIGATOR_21392] -ASP Steering Committee . Similarly, if an  ES 
antibiotic is selected that t argets a resistant Gr am-negative Enterobacteriaceae, the ordering 
physician will receive information on the probability that the patient is likely to grow such organisms.  
The smart prompt will account for personal attributes of the patient as well as local 
resistance patterns.  Hospi[INVESTIGATOR_341072], principally involving  a decision support tool known as Rx VigiLanz Therape utic Advisor,191 
which has been adopted by  [CONTACT_341145][INVESTIGATOR_600]. This tool alerts stewardship teams of possible 
opportunities for intervention, based on microbiology results. Intervention hospi[INVESTIGATOR_341073].  
The study populati on is defined at the hospi[INVESTIGATOR_172882], w here the interve ntion will be adopted 
as part of a hospi[INVESTIGATOR_307] -wide antibiotic stewardship quality improvement initiative targeting non-ICU 
adult patients admitted with UTI. Hospi[INVESTIGATOR_341074] B.1.3.  
 
 
 
Table 1: INSPI[INVESTIGATOR_341075] -Spectrum Antibiotics  
Pathogen -Directed 
Antibiotic Category  Extended -Spectrum Antibiotics Targeted in INSPI[INVESTIGATOR_341076]-MRSA  Ceftaroline, Daptomycin, Linezolida, Vancomycinb 
Anti-VRE Daptomycin, Linezolid  
Antipseudomonal  Aztreonam, Cefepi[INVESTIGATOR_048], Ceftazidime, Pi[INVESTIGATOR_049]/Tazobactam  
Anti-ESBL  Ertapenem, Meropenem, Imipenem , Ceftolozane/Tazobactam  
Anti-CRE  Ceftazidime/Avibactam, Colistin, Imipenem/Relebactam, Meropenem/Vaborbactam,  
Polymixin B, Tigecycline  
 
 
B.1.[ADDRESS_422217], we will provide 
webinars through HCA  Healthcare‚Äôs  webhosting system to int roduce the trial and call for 
participation. Second, a call for participati on will be made by [CONTACT_341146]. Third , our HCA  Healthcare co-
investigators, who are system -wide leaders o f antibiotic stewardship, quality, and infection 
prevention, will provide d irect-to-hospi[INVESTIGATOR_341077]. Recruitment announcements will 
utilize usual corporate and local  HCA  Healthcare communication channels and will be directed at 
hospi[INVESTIGATOR_341078]/infectious dis eases leaders. 
Participation will be confirmed by a signed letter of participation from the individual hospi[INVESTIGATOR_600]‚Äô  CEOs.  
For each hospi[INVESTIGATOR_341079] , enrollment  criteria will be assessed by 
[CONTACT_341147] s. First, a contact [CONTACT_341148]. Second, a facility 
survey will be distributed to confirm eligibility criter ia and obtain information on hospi[INVESTIGATOR_341080] c stewardship program activities .  As done in our previous HCA  
Healthcare trials , surveys will be administered through HCA  Healthcare‚Äôs  usual survey channels 
and results will be compi[INVESTIGATOR_341081] a database format . 
 
B.1.[ADDRESS_422218] Pi[INVESTIGATOR_192334] (HPHC) 
IRB. HCA  Healthcare‚Äôs corporate regulator y affairs  and risk management  liaison  will facilitate 
delegation of IRB governance from each particip ating hospi[INVESTIGATOR_341082] -approved programs.   This intervention of a quality improvement strategy 
for antibi otic stewardship meets national regulatory standards  for waiver of informed consent under 
the Office of Human Research Protections (OHRP) criteria 45 CFR 46.116(d), 117(c) (2) and Food 
and Drug Administration (FDA) CFR 56.109(c) (1).(38) since 1) trial act ivities meet minimal risk 
criteria, 2) the trial rando mizes hospi[INVESTIGATOR_600], not patients,  to a quality imp rovement strategy,  3) the 
intervention is not designed to supplant physician judgment, but rather provide relevant information 
to prescribing physicians who will be educated to choose the treatment they deem m ost clinically 
appropriate for individual patien ts, and 4) all assigned activities will be performed according to  usual  aBoth oral and intravenous (IV) formulations  
bIV formulation only.  
Abbreviations: CPOE  ‚Äì Computerized Provider  Order Entry, MRSA ‚Äì Methicillin -Resistant Staphylococcus aureus,  
ESBL ‚Äì Extended -Spectrum Beta -Lactamase Producing  ESBL Enterobacterales  including  Acinetobacter  and  
Pseudomonas species with multidrug -resistance to antipseudomonal antibiotics but can be treated with a  carbapenem  
or ceftolozane/tazobactam , CRE  ‚Äì Carbapenem -Resistant Enterobacterales , including  Carbapenem -Resistant  
Acinetobacter  and Pseudomonas  species .
hospi[INVESTIGATOR_341083]. We will also collect attestations from hospi[INVESTIGATOR_341084].   
 
B.1.5 Randomization  
While this study represents a large cluster -randomized trial of hospi[INVESTIGATOR_600], simple 
randomization of hospi[INVESTIGATOR_341085], and without 
care could even result in very unequal numbe rs of hospi[INVESTIGATOR_341086]. Achieving balance on key 
features of the random ization units (in this case, hospi[INVESTIGATOR_600]) is a critical task in cluster -randomized 
trials, but little literature on it exists. Unlike i ndividually randomized  trials, information abou t the 
clusters is often known in advance, but the number of clusters to be r andomized can be relatively 
small. The existence of a priori data can mitigate the small numbers and help to obtain adequate 
balance through stratification or other methods. One at tractive approach is to establish tuplets ‚Äî
matched sets (pairs, for a two- arm trial) ‚Äì in which one member of each tuplet is assigned to each 
arm. Schemes f or constructing tuplets need not be guided by [CONTACT_75780]. A formal approach would be 
to calculate the Maha lanobis distance between hospi[INVESTIGATOR_341087]. In this approach, we could st andardize the 
variables, and then multiply by [INVESTIGATOR_78243] c alibrated to reflect any difference in the impor tance of 
balancing them. Other approaches are more ad hoc, such as prioriti zing broad classes of balance 
on a key variable and making pairs within these s trata based on lower -priority variables. However, 
there is no ‚Äúbest‚Äù method of tuplet construction, o nly sets that come closer to meeting the varied 
needs of each trial.  
We will establish the pairs under several plausible tuplet -construction schemes, and use 
graphical methods to compare all possible real izations for balance between the arms under each 
scheme. For example, if two variables were to be balanced, we would tentatively divide the sample 
into two groups under a tuplet con struction scheme and then generate a scatterplot showing the 
between- arm ab solute value of the mean difference for one variable on the x -axis and the second 
on the y -axis for each possible result of the randomization. We would then divide the groups again 
under the same scheme, and find another point on the scatterplot. Repeating many times would 
show the typi[INVESTIGATOR_341088] a scheme. Comparing the resulting scatterplots from each tuplet -construction scheme can reveal the relative ris ks of imbalance and benefi ts for 
balance accruing to each randomization scheme, in a practical sense. One tuplet construction 
method may result in generally close balance on one key characteristic and very variable balance 
on the other, while a competing s cheme has good median balance on both characteristics, but 
where each has a long tail implying a few bad- luck assignments with poor balance.  
We hope to consider balance on more than two factors, and for assessing the impact on 
balance in this case,  we will  use a parallel coordinat es plot, a multivariate plot method. After 
determi ning key variables where balance across the arms would be highly desirable, we will plot the  
mean difference between the arms for all key variables for each potential realized rando mization.  
We will focus on balancing the baseline outcome values in partic ipating hospi[INVESTIGATOR_341089], local 
prevalence of antibiotic resistance in UTI patients,  length -of-stay, ICU transfers, and facility case -
mix of patients with UTI . Hospi[INVESTIGATOR_341090] a 
single hospi[INVESTIGATOR_341091].  
 
B.1.6 Baseline  Period Activities  
 The baseline period will be a 1 8 month  period from April 1, 2017 ‚Äì September 30, 2018,  
prior to the phase in and will share a similar  month distribution as the intervention period. This 
period will provide baseline outcome dat a for both arms (see Analysis Secti on B.1.10). In addition 
to recruitment and randomi zation, preparatory activities for Phase- In and Intervention Periods will 
also begin. The corporate HCA Information Technology (IT) team will develop the CPOE smart 
prompt template which will include creati on of smart prompt algorithms, automated compliance 
reports, and centralized beta test ing. CPOE smart prompts will use MDRO infection risk estimates 
developed in a separate  retrospective cohort study.   Educational materials and training modules will 
be dev eloped as described below .  
  
B.1.[ADDRESS_422219], the implementation of the CPOE smart prompt requires both corporate and 
local IT department efforts. This will req uire time to accurately implement and ensure sufficient 
validation and refinement for proper function at each participat ing intervention arm hospi[INVESTIGATOR_307].  
During this period, educational material s will be distributed to study champi[INVESTIGATOR_341092] (Table  2). In addition, study site champi[INVESTIGATOR_341093] -In period, ultimately transitioning 
to every other month calls when implementation and feedback stabili zes. Special coaching calls will 
also occur at least quarterly for both arms and invo lve best practice stewardship recomm endations 
from national guidelines and experts. All coaching calls will be led by [CONTACT_341149] t by [CONTACT_341150]. Coaching calls will involve a shared 
PowerPoint slide set followed by a question and answ er session. All coaching calls will be recorded 
and placed on arm -specific INSPI[INVESTIGATOR_21392] -ASP Trial sites on the HCA Healthcare intranet for c ontinued 
access by [CONTACT_341151]. Participant s will be highly e ncouraged to share 
concerns and solutions with one another.  
 
Table  2. INSPI[INVESTIGATOR_21392] -ASP UTI Trial Educational Binder and Distributed Material  
Topic  Description  
1. Trial Summary  Goals and investigative team  
2. Frequently Asked 
Questions  Answers to common questions a bout the trial or 
protocol .   
3. Roles  and 
Responsibilities  Description of expected roles and responsibilities of 
pharmacy and physician antibiotic stewardship 
champi[INVESTIGATOR_5458]  
4. Talking Points  Talking points for common physician  and pharmacist 
questions about the trial or protocol  
5. Committee Protoco l or 
Policy Proposal  Description of CPOE smart prompt antibiotic 
stewardship initiative for committee approval submission 
to adopt as h ospi[INVESTIGATOR_341094]  
6. Kick-Off PowerPoint  PowerPoint slides used in the kick -off webinar  
7. Physician Education 
Powe rPoint 
Presentations  Description of, and basis for, guidance on appropriate 
antibiotic use for UTI, definition of extended- spectrum 
antibiotic groups, the INSPI[INVESTIGATOR_21392] -ASP MDRO risk 
estimate and smart prompt , and compliance f eedback 
reports.  
8. Feedback  Process for study champi[INVESTIGATOR_341095]  
 
 B.1.8 Intervention Phase Activities  
The automated point -of-care pr ecision medicine CPOE smart prompts will be implemented 
at each fac ility randomized t o the intervention arm .  Automated c ompliance feedback reports 
detailing prescriber response to CPOE prompt recommendations will be generat ed on a rolling 3 -
month basis  (or sooner if available) , including reasons for continuing with extended spectrum 
antibiotic prescribing.  Pharmacy/physici an study champi[INVESTIGATOR_341096].  
We will have a dedicated study email and toll -free number for s tudy questions.  Hospi[INVESTIGATOR_341097].  
For both study arms, study site champi[INVESTIGATOR_341098] a) no new hospi[INVESTIGATOR_341099].  If a site reports a new hospi[INVESTIGATOR_341100] a direct conflict with the INSPI[INVESTIGATOR_21392] -ASP trial, they w ill be asked t o 
report the initiative to the trial Steering Committee for determination of trial conflict. Hospi[INVESTIGATOR_341101].   
 
B.1.9 INSPI[INVESTIGATOR_21392] -ASP UTI Trial Outcomes  
The goal of this trial is to reduce unnecessary physician prescribing of empi[INVESTIGATOR_341102] -
spectrum antibi otics (Table 8) . Trial outcomes evaluating intervention effectiveness are outlined in 
Table [ADDRESS_422220] three days of an admission and divided by [CONTACT_341152][INVESTIGATOR_341103].  An empi[INVESTIGATOR_341104] a day within the firs t three days of an 
admission. We define this outcome as an Extended- Spectrum Days Of Therapy (ES -DOT) per 
empi[INVESTIGATOR_341105].   Days of therapy (DOT) is specific to each extended- spectrum antibiotic, where any 
dose is considered one day‚Äôs wort h of t herapy. The ES a ntibiotics are then aggregated to obtain the 
total ES DOT. For example, if a patient is started on vancomycin and cefepi[INVESTIGATOR_341106] 1 day, this will count as 2 ES DOT for that day. Multiple doses of the same antibiotic received on the same day are 
only counted  as one day of therapy for that extended spectrum antibiotic. This outcome will include 
antibiotics in Table1 .  
 
Table  3: Primary and Secondar y INSPI[INVESTIGATOR_21392] -ASP UTI Trial Outcomes  
Outcome  Metric  
Primary Trial Outcome  
Extended-Spectrum D ays Of Antibacterial 
Therapy (ES-DOT) per Empi[INVESTIGATOR_29121] D ay The sum med number of different extended -spectrum antibacterials  
received each empi[INVESTIGATOR_341107], measured repeatedly  over the first three 
days of an admission and divided by [CONTACT_341153][INVESTIGATOR_341108]. An empi[INVESTIGATOR_341104] a day within the first three day s of 
an admission .1 
Secondary Trial Outcomes  
Vancomycin Days of Antibacterial Therapy  
per Empi[INVESTIGATOR_341109] -risk-day (first 3 days of  admission)1 
Antipseudomonal Antibiotic Days Of 
Therapy (ES-DOT) per Empi[INVESTIGATOR_29121] D ay The summ ed number of different antipseudomonal  antibacterials  
received each empi[INVESTIGATOR_341107], measured repeatedly over the first three 
days of an admission and divided by t he number of  empi[INVESTIGATOR_341110].  An empi[INVESTIGATOR_341104]  a day within the first three days of 
an admission .1,2 
1E.g., if a patient is admitted for 2 days, ES -DOT will be calculated for 2 days and divided by 2 empi[INVESTIGATOR_341111]; 
conversely if a patient is admitted for [ADDRESS_422221] 3 days will be evaluated .  
2Does not include aminoglycosides or fluoroquinolones.  
 
Safety outcomes planned for the primary manuscript are shown in Table  4. Safety outcomes will be 
analyzed separately from the main effec tivenes s outcomes of the trial (see Primary Statistical 
Analy sis section below).  
 
Table  4: Other Pre -Specified Outcomes  ‚Äì Safety Trial Outcomes  
Safety Trial Outcome s (other pre -specified outcomes)  
Antibacterial Escalations  [Safety 
Outcome]  Days from star t of st andard -spectrum antibacterial until switch to 
extended -spectrum antibacterial during hospi[INVESTIGATOR_341112] [Safety Outcome]  Days from start of hospi [INVESTIGATOR_341113] -of-stay [Safety Outcome]  Days f rom hos pi[INVESTIGATOR_157434]  
 
 
B.1.[ADDRESS_422222] three days of an admission. We define this outcome as an Extended- Spectrum Days 
Of Therapy (ES -DOT) per empi[INVESTIGATOR_341105]. For clarity the calculation is as follows: we define a DOT for 
a particular ES antibiotic as a day in which any number of doses of that antibiotic is given. Different 
ES antibiotics are summed across the empi[INVESTIGATOR_341114], then divided by [CONTACT_341154][INVESTIGATOR_341115] -admiss ion to determine each admission‚Äôs DOT per at -risk day. If an 
admission is less than [ADDRESS_422223] an ICD -10 claims 
code indicating UTI is present on admission, who received any antibiotic within 3 days of 
admiss ion, and who were admitted to a non -ICU location. For admissions initially on a non- ICU 
floor and transferred to the ICU, analysis will include only admission days on the non -ICU floor 
within 3 days of admission.  
The trial periods are defined as follows: (1) Baseline ‚Äì April 1, 2017 ‚Äì September 30, 2018 
(18 m onths); (2) Phase -in ‚Äì October 1, 2018 ‚Äì March 31, 2019 (6 months); (3) Intervention  
‚ÄìApril 1, 2019 ‚Äì June 30, 2020 (15 months).
The unit of analysis will be individual admissions. Individuals can contribute more than one 
admission. The analytic model will be a generalized linear mixed effects model for differences in 
differences, with random effects accounting for correlation within cluster, period- varying random 
effects to allow for differences between hospi[INVESTIGATOR_341116] -up, and admission- level 
random effects to account for correlation within person and hospi[INVESTIGATOR_307].  Analyses of the baseline data, 
performed before randomization, found no evidence of overdispersion in a Poisson model, and so  
we plan to use that model for analysis of outcomes. The model can be expressed as follows:  
wher e ùë¶ùë¶ùëñùëñùëñùëñùëñùëñ‚Ñé is the ES -DOT per at -risk day for pat ient ùëñùëñ for ad mission ùëñùëñ in period ùëñùëñ at hosp ital ‚Ñé, and 
ùê¥ùê¥ùëñùëñùëñùëñùëñùëñ‚Ñé = 1 if hospi[INVESTIGATOR_307] ‚Ñé is in the intervention a rm and 0 if  not, and ùëáùëáùëñùëñùëñùëñùëñùëñ‚Ñé = [ADDRESS_422224] e admissions.  Equivalently,  they al low for correlation within hospi[INVESTIGATOR_307] a t 
different l evels a t base line and at f ollow -up. 
The assessment o f trial s uccess  will be determined by t he significance of t he arm by [CONTACT_341155] t erm ùõΩùõΩ 3, which assesses w hether the log relative r ate of the outcome due t o bei ng in the 
intervention ar m in the i ntervention period is di fferent from 0 . The exp onentiated 
parame ter estimate fo r ùõΩùõΩ3 is t he es timate d relative rate of E S-DOT p er at-risk day due to the 
intervention, relative  to the baseline period. For e xample, i f ùõΩùõΩ3 had a negative value and a p- value 
<0.05, w e woul d conclude that the patient -specific CP OE s mart p rompts  generated a benefit ove r 
routine care. E xponentiating the parameter va lue would provides an es timate of t he relative 
reducti on due t o the interventi on in t he expected E S-DOT p er at-risk day. 
The primary trial anal ysis w ill use  an as -randomized unadjusted m odel w ith two-t ailed 
significance set at al pha = 0 .05. S econdary out comes al so will be assessed using an as - 
randomized unadj usted model w ith adjustment for multiple comparisons w ith two -tailed significance  
set a t alpha = 0. [ADDRESS_422225] conservative manner 
to identify potential safety issues. This is required because a reduction in ES -DOT might be 
achieved onl y by [CONTACT_341156]. Each saf ety 
outcome will be evaluated for non -inferiority using an as -randomized unadjusted model with a one -
tailed significance set at alpha = 0.05. Analyses planned for these asses sments are proportional 
hazards models with random effects (to account for hospi[INVESTIGATOR_341117]). These models are sometimes 
called frailty or shared frailty models. Because these are safety outcomes, we do not intend to 
make adjustments for multiple comparisons in testing them, f urther increasing conservatism.  
All analyses will be performed using current versions of SAS (Version 9.4, as of writing, SAS 
Institute, Cary NC) and/or R (Version 4.0, as of writing).  
 
B.1.11 Power Size/Sample Size Calculations  
Power assessment proceeded as fol lows, using a Monte Carlo approach. We used 
available data to define a baseline period of 10/1/2015- 12/31/2016 in a bootstrap procedure. 
Individuals were selected with replacement from within each hospi[INVESTIGATOR_307], once to represent 
baseline data and separately to  represent intervention period data. In the randomizati on 
portion of the Monte Carlo approach, we ordered the hospi[INVESTIGATOR_341118] ‚Äúsize‚Äù, meaning the 
number of admissions with UTI. Then, within strata of 6 hospi[INVESTIGATOR_600], we ordered by [INVESTIGATOR_5165] -DOT 
per at -risk day. Then we took pairs of hospi[INVESTIGATOR_341119] -DOT per at -risk day and 
assigned one member of the pair to one arm. To do this, a single pseudo- random number 
uniformly distributed between 0 and 1 was generated for each pair. If it was l ess than 0.5, the 
arbitrary  ‚Äúfirst‚Äù member of the pair was assigned to Routine Car e and the other to 
Intervention. If it was greater than or equal to 0.5, then the assignments were reversed. The 
remaining unpaired hospi[INVESTIGATOR_66537] 59 units were assigned as the ‚Äúfirst‚Äù member of a pai r with 
no match. (Three set s of hospi[INVESTIGATOR_341120] a stewardship program and these hospi[INVESTIGATOR_341121] a single hospi[INVESTIGATOR_341122].)  
If an admission was in the intervention arm in the intervention period, then t heir ES -DOT 
per a t-risk day was reduced by a proportion, given below. The reduction of ES -DOT per at -risk 
day was selected with a lower bound determined by [CONTACT_341157]- for effect of 
the intervention with minimal clinical significance, and the impact in t he Monte Carlo calculation 
on a per -admission basis was to reduce the days of therapy proportionately between this 
number and 1, on a uniform distribution. In other words, if the effect of the intervention was to 
multiply doses by [CONTACT_341158] e as .9, each per son would have their doses multiplied by [INVESTIGATOR_82473] .[ADDRESS_422226] 12.5% relative to usual care. Using the method 
above, we have 97% power (CI 91 -99%) to detect this effect. Table  5 below shows the 
calculated power and confidence intervals for the primary and secondary outcomes to be 
evaluated in our primary manuscript.  
 
Table  5. Power Cal culation ‚Äì Primary and Secondary Outc omes  
Primary Tria l Outcome  Power (CI), %  
Extended -Spectrum Antibacterial Days Of Therapy 
(ES-DOT) per Empi[INVESTIGATOR_341123] y 97 (91 -99) 
Secondary Trial Outcomes   
Vancomycin Days of Therapy  per Empi[INVESTIGATOR_27969] c Day  92 (85 -96) 
Antipseudo monal Antibiotic Days Of Therapy (ES -
DOT) per Empi[INVESTIGATOR_341124] 84 (77 -91) 
 
  
References Cited  
1. Magill SS, Edwards JR, Beldavs ZG, Dumyati G, Janelle SJ, Kainer MA, Lynfield R, Nadle J, 
Neuhauser MM, Ray SM, Richards K, Rodri guez R, Thompson DL, Fridkin SK; Emerging 
Infections Program Healthcare- Associ ated Infectio ns and Antimicrobial Use Pr evalence Survey 
Team. Prevalence of antimicrobial use in US acute care hospi[INVESTIGATOR_600], May -September 2011. JAMA  
2014;312(14):1438 -46. 
2. Fridkin S , Baggs S, Fagan R, Magill S, Pollack LA, Malpi[INVESTIGATOR_341125] P, Slayton R, Khader K, Rub in MA, 
Jones M, Samore MH, Dumyati G, Do dds-Ashley E, Meek J, Yousey -Hindes K, Jernigan J, 
Shehab N, Herrera R, McDonald CL, Schneider A, Srinivasan A; Centers for Disease Control 
and Prevention (CDC). Vital signs: improving antibiotic use among hospi[INVESTIGATOR_341126]. 
MMWR Morb Mortal Wkly Rep 2014;63:194 -200. 
3. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the [LOCATION_002], 
2013. Available at: http:/ /www.cdc.gov/drugresistance/pdf/ar -threats -2013 -508.pdf. Accessed 
on May 19, 2 015. 
4. Marston HD, Dixon DM, Knisely JM, P almore TN, Fauci AS. Antimicrobial Resistance. JAMA. 
Sep 20 2016;316(11):1193- 1204.  
5. Arcilla MS, van Hattem JM, Haverkate MR, et al. Import  and spread of extended- spectrum beta-
lactamase -producing Enterobacteriaceae b y international travellers (COMBAT study ): a 
prospective, multicentre cohort study. Lancet Infect Dis. Oct [ADDRESS_422227] 
Dis 2005;11(6):[ADDRESS_422228] Control Hosp Epi[INVESTIGATOR_5541]  2011;32:714- 8. 
8. Boucher HW, Talbot GH, Bradley JS, Edwar ds JE, Gilber t D, Rice LB, Scheld M, Spe llberg B, 
Bartlett J. Bad bugs, no drugs: No ESKAPE! An updated from the Infectious Diseases Society 
of America. Clin Infect Dis  2009;48:1- 12. 
9. Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, M urray BE, 
Bonomo RA, Gilbert D. 10 x '[ADDRESS_422229] gram -
negative bacilli: an update from the Infectious Diseases Society of America. Clin I nfect Dis  
2013;56:1685 -94. 
10. Centers for Disease Control and Prevention. Get Sm art for Healthcare. Available at: 
http://www.cdc.gov/getsmart/healthcare/. Accessed May 8, 2015.  
11. Executive Office of the Presidents, President‚Äôs Council of Advisors on Science and Technology. 
Report to the President on Combating Antibiotic Resistance. Avai lable at: 
https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2
014.pdf. Accessed on May 8, 2015.  
12. The White House. National Strategy for Combating Antibiotic -Resistant Bacteria. Available at: 
https://www.whitehouse.gov /sites/default /files/docs/carb_national_s trategy.pdf. Accessed on 
May 19, 2015.  
13. Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating National Trends in 
Inpatient  Antibiotic Use Among US Hospi[INVESTIGATOR_341127] 2006 to 2012. JAMA Intern Med. Nov 1 
2016;176(11):[ADDRESS_422230], Jacobs S, Liberatore K, Palfreyman MA, Harrison 
EI, Cardo DM; CDC Campaign to Prevent Antimicrobial Resistance Team. Clinicians‚Äô 
perceptions of the problem of antimicrobial resistance in he althcare faci lities. Arch Intern Med  
2004;164:[ADDRESS_422231] Control Hosp Epi[INVESTIGATOR_5541]  2014;35(Suppl 3):S69- 78. 
16. Barlam TF, Cosg rove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: 
Guidelines by [CONTACT_341159][INVESTIGATOR_341128]. Clin Infect Dis. May 15 2016;62(10):e51 -77. 
17. Provonost P, Berenholtz SM , Needham DM. Translating evidence into practice: a model for 
large scale knowledge translation. BMJ  2008;337:a1714.  
18. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD,  Dean NC, Dowell SF, File 
TM Jr, Musher DM, Niederman MS, Torres A, Whitney C G. Infectious Diseases Society of 
America /American Thoracic Society Consensus Guidelines on the Management of Community -
Acquired Pneumonia in Adults. Clin Infect Dis  2007;44:S27- 72. 
19. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicol le LE, Raz R,  
Schaeffer AJ, Soper DE. In ternational Clinical Practice Guidelines for the Treatment of Acute 
Uncomplicated Cystitis and Pyelonephritis in Women: A [ADDRESS_422232] Dis  2011;52:e103 -20. 
20. Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections 
(UTIs). Can J Urol 2012;[ADDRESS_422233] 1:[ADDRESS_422234] Dis  
2014;20:[ADDRESS_422235] S, Fraser V J. Inadequate antimicrobial treatment of infections: a 
risk factor for hospit al mortality a mong critically ill patient s. Chest  1999;115:462- 74. 
23. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin- resistant 
Staphylococcus aureus  sterile -site infection: the importance of appropriate initial antimicrobial 
treatment. Crit Care Med 2006; 34: 2069- 74. 
24. Micek ST,  Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa 
bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob 
Agents Chemother  2005;49:1306- 11. 
25. Kang CI , Kim SH, Park  WB, Lee KD, Kim HB, Kim EC , Oh MD, Choe KW. Bloodstream 
infections caused by [CONTACT_246979] -resistant gram -negative bacilli: risk factors for mortality and 
impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemo ther 
2005; 49:760 -6. 
26. Self WH, Wunderink RG , Williams DJ, et al. Staphylococcus aureus Community -acquired 
Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis. Aug 1 
2016;63(3):[ADDRESS_422236]. Aug 2016;150(2):[ADDRESS_422237] ug-resistant pathogens in immunocompetent 
patients with pneumonia: Evaluation of PES pathog ens. J Infect Chemother. Oc t 8 2016.  
29. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the 
management of adults with hospi[INVESTIGATOR_307] -acquired, ventilator -associated, and healthcare- associated 
pneumonia. Am J Respir Cr it Care Med  2005;171:388- 416. 
30. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS . Epi[INVESTIGATOR_341129]- care-associated pneumonia: results from a large US da tabase of culture- positive 
pneumonia. Chest  2005;128:3854- 62. 
31. Ewig S, Welte T , Chastre J, T orres A . Rethinking the concepts of community -acquired and 
health- care-associated pneumonia. Lancet Infect Dis  2010;10:279 -87. 
32. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospi[INVESTIGATOR_307] -acquired and 
Ventilator -associated Pneum onia: [ADDRESS_422238] Dis. Sep 1 2016;63(5):e61 -
e111.  
33. Park KH, Oh W S, Kim ES, Park SW, Hur JA, Kim YK, Moon C, Lee JH, Lee CS, Kim BN. 
Factors associ ated with ciprofloxacin-  and cefotax ime-resistant  Escherichia coli in women with 
acute pyelonephritis in the emergency department. Int J Infect Dis  2014;23:8- 13. 
34. Huttner B, J ones M, Huttner A, Rubin M, Samore MH. Antibiotic prescription practices for 
pneum onia, ski n and soft tissue infections and urinary tract infections throughout the US 
Veterans Affairs system. J Antimicrob Chemother  2013;68:2393 -9. 
35. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare -associated pneumonia does not 
accurately identify po tentially res istant pathogens: a systematic review and meta- analysis. Clin 
Infect Dis  2014;58:330- 9. 
36. Grenier C, Pepin J, Nault V, Nault V, Howson J, Fournier X, Poirier MS, Cabana J, Craig C, 
Beaudoin M, Valiquette L. Impact of guideline- consistent therapy on outcome o f patients with 
healthcare- associated and community -acquired pneumonia. J Antimicrob Chemother  
2011;66:1617 -24. 
37. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L,  Pugh MJ, Anzueto A, Mortensen EM. 
Guideline- concordant therapy and outcomes i n healthcare- associated pneumonia. Eur R espir J  
2011;38:878 -87. 
38. Troitino AX, Porhomayon J, and El -Solh AA. Guideline- concordant antimicrobial therapy for 
healthcare- associated pn eumonia: a systematic review and meta- analysis. Lung  2013;191:229-
37. 
39. Lee SS,  Kim Y, and Chung DR. Impact of discordant empi[INVESTIGATOR_341130] -acquired bacteremic acute pyelonephritis. J Infect  2011;62:159- 164. 
40. Jeon JH , Kim K, Han WD , Song SH, Park KU, Rhee JE, Song KH, Park WB, Kim ES, Park SW, 
Kim NJ, Oh MD, Ki m HB. Empi[INVESTIGATOR_98599] l use of ciprofloxacin for acute uncomplicated pyelonephritis 
caused by [CONTACT_341160]. A ntimicrob Agents Chemother  2012;56:3043- 6. 
41. Webb BJ, Dascomb K, Stenehjem E, D ean N . Predict ing risk of drug -resistant organisms in 
pneumonia: Moving beyond the HCAP model. Respir Med 2015;109:[ADDRESS_422239] Dis  2011;53: 42-8. 
43. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsay CR, Wiffen PJ, Wilcox 
M. Interventions to improve antibiotic pres cribing practices for hospi[INVESTIGATOR_39485]. Cochrane 
Database Syst Rev  2013;4: CD003543.  
44. Brow n K, Valenta K, Fishman D, Simor A, Daneman N. Hospi[INVESTIGATOR_341131]. JAMA Intern Med 2015;175:626 -33. 
45. Braykov NP, Morgan DJ, Schweizer ML, Uslan DZ, Kelesidis T, Weisenberg SA, Johannsson B, 
Young H, Cantey J, Srinivas an A, Perencevich E, Septimus E , Laxminarayan R. Assessment 
of empi[INVESTIGATOR_341132]: an observationa l cohort study. 
Lancet Infect Dis  2014;14:1220- 7. 
46. Fowler S, Webber A, Cooper B S, Phimister A, Price K, Carter Y, Kibbl er CC, Simpson AJ, 
Stone SP. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium 
difficile  infection: a controlled interrupted time series. J Antimicrob Chemother  2007;59:990 -5. 
47. Charan i E, Kyratsis  Y, Lawson W, Wickens H, Br annigan ET, Moore LS, Holmes AH. An 
analysis of the development and implementation of a smartphone application for the delivery of 
antimic robial prescribing policy: lessons learnt. Antimicrob Chemother  2013;68:[ADDRESS_422240] of policy guidelines on hospi[INVESTIGATOR_341133] a decade: a segmented time series  
analysis. PLoS ONE 2014;9:e92206.  
49. Hamilton KW, Gerber JS, Moehring R, Anders on DJ, Calderw ood MS , Han JH, Mehta JM, 
Pollack LA, ZaoutisT, Srinivasan A, Camins BC, Schwartz DN, Lautenbach E; Centers for 
Disease Control and Prevention Epi[INVESTIGATOR_295903]. Point -of-prescription intervention to 
improve antibiotic stewardship. Clin Infe ct Dis 2015;60:1252 -8. 
50. Cooke FJ and Holmes AH. The missing care bundle: antibiotic prescribing in hospi[INVESTIGATOR_600]. Int J 
Antimicrob Agents  2007;30:25- 9. 
51. Rodriquez -Maresca M, Sorlozano A , Grau M, Rodriquez -Castano R, Ruiz -Valverde A, 
Gutierrez -Fernandez J. Implem entation of a computerized decision suppo rt system to improve 
the appropriateness of antibiotic therapy using local microbiologic data. Biomed Res Int  
2014;2014:395434.  
52. Deuster S,  Roten I, Muehlebach S. Implementation of treatment guidelines to support judi cious 
use of antibiotic therapy. J Clin Pharm Ther  2010;35:71- 8. 
53. Pogue JM, Alaniz C, Carver PL, Pleva M, Newton D, DePestel DD. Role of unit -specific 
combination antibiograms for  improving selection of appropriate empi[INVESTIGATOR_341134] -
negative pneumoni a. Infect Con trol Hosp Epi[INVESTIGATOR_5541]  2011;32:289- 92. 
54. Rabs N, Wieczorkiewicz SM, Costello M, Zamfirova I. Development of a urinary -specific 
antibiogram for Gram negative isolates: impact of patient risk factors on susceptibility. Am J 
Infect Control  2014;42:393 -400. 
55. Karam G , Chastre J, Wilcox MH, Vin cent JL. Antibiotic strategies in the era of multidrug 
resistance. Crit Care. Jun 22 2016;20(1):136.  
56. Auffray C, Caulfield T, Griffin JL, K houry MJ, Lupski JR, Schwab M. From genomic medicine to 
precision medicine: hi ghlights of 2015. Genome Med. Jan 29 2016;8(1):12.  
57. Chambers DA, Feero WG, Khoury MJ. Convergence of Implementation Science, Precision 
Medicine, and the Learning Health Care System: A New Model for Biomedical Research. 
JAMA. May 10 2016;315(18):1941- 1942.  
58. Khoury MJ, Gal ea S. Will Precision Medici ne Improve Population Health? JAMA. Oct 4 
2016;316(13):1357 -1358.  
59. Khoury MJ, Iademarco MF, Riley WT. Precision Public Health for the Era of Precision Medicine. 
Am J Prev Med. Mar 2016;50(3):[ADDRESS_422241] AC , Richards MJ, Brown GV. 
Electronic antibiotic stewardship‚Äîreduced consumption of broad- spectrum antibiotics using a 
computerized antimicr obial approval system in a hospi[INVESTIGATOR_6885]. J Antimicrob Chemother  
2008;62:[ADDRESS_422242] of regular collaboration between 
infectious diseases and critical care practitioners on antimicrobial utilization and patient 
outcome. Crit Care Med  2013;41:[ADDRESS_422243] rounds and a dedicated prescription chart reduce antibiotic 
consumption and pharm acy costs with out affecting  inpatient mortality or re -admission rates. 
PLoS One  2013;8:e79747.  
63. Schulz L, Osterby K, Fox B. The use of best practice alerts with the development of  an 
antimicrobial stewardship navigator to promote antibiotic de- escalation i n the electronic medical 
record. Infect C ontrol Hosp Epi[INVESTIGATOR_5541]  2013;34:1259- 65. 
64. Lee TC, Frenette C, Jayaraman D, Green L, Pi[INVESTIGATOR_63772] L. Antibiotic self -stewardship: trainee- led 
struct ured antibiotic time -outs to improve antimicrobial use. Ann Intern Med  2014;16 1([ADDRESS_422244]):S 53-8. 
65. Lesprit P, de Pontfar cy A, Esposito -Farese M, Ferrand H, Mainardi JL, Lafauri M, Parize P, 
Rioux C, Tubach F, Lucet JC. Postprescription review improves in- hospi[INVESTIGATOR_341135]: a 
multicenter randomized controlled trial. Clin Microbio l Infect 2015 ;21:180.e1- [ADDRESS_422245] Dis  1984;[ADDRESS_422246] 3:S759- 68. 
67. Huang SS, Platt R . Risk of methicillin -resistant Staphylococcus aureus  infection after previous 
infection or col onization. Clin Infect Dis  2003;36:281- 5. 
68. Shojania KG, Yokoe D, Platt R , Fiskio J, Ma'luf N, Bates DW. Reducing vancomycin use 
utilizing a computer guideline: result s of a randomized controlled trial. J Am Med Inform Assoc  
1998;5:[ADDRESS_422247] 
Control Hosp Epi[INVESTIGATOR_5541]  2003;24:13 -6. 
70. Simon SR, Smith DH, Feldstein AC, Perrin N, Ya ng X, Zhou Y, Platt R , Soumerai SB. 
Computerized prescribing alerts and group academic detailing to reduce the use of potentially 
inappropriate medications in older people. J Am G eriatr Soc  2006;54:[ADDRESS_422248]: an 
interrupted time series evaluation. Arch Intern Med  2006;166:1098- 104. 
72. Langford BJ, Seah J, Chan A, Downing M, Johnston e J, Matukas LM. Antimicrobial 
Stewardship in the Microbiology Laboratory: Impact of Selective Susceptibility Reporting on Ciprofloxacin Utilization and Susceptibility of Gram -Negative Isolates to Ciprofloxacin in a 
Hospi[INVESTIGATOR_204094]. J Clin Microbiol. Sep  2016;54(9):[ADDRESS_422249] Dis. Nov 15 2016;63(10):1273- 1280.  
74. Goldstein EJ, Goff DA, Re eve W, et al. Approaches to Modifying the Behavior of Clinicians Who 
Are Nonc ompliant With Antimicrobial Stewardship P rogram Guidelines. Clin Infect Dis. Aug 15 
2016;63(4):532 -538. 
75. Emanuel EJ, Ubel PA, Kessler JB, et al. Using Behavioral Economics to Design Physician 
Incentives That Deliver High- Value Care. Ann Intern Med. Jan 19 20 16;164(2):114- 119. 
76. Madaras -Kelly KJ, Rem ington RE, Fan VS, Sloan KL. Predicting antibiotic resistance to 
community -acquired pneumonia antibiotics in culture- positive patients wit h healthcare -
associated pneumonia. J Hosp Med. Mar 2012;7(3):[ADDRESS_422250] 1 2016;63(7):896- 903. 
78. Anesi JA, Lautenbach E, Nachamkin I, et  al. Clinical and Molecular Characterizat ion of 
Community -Onset Urinary Tract Infections Due to Extended- Spectrum Cephalosporin- Resistant 
Enterobacteriaceae. Infect Control Hosp E pi[INVESTIGATOR_5541]. Sep 28 2016:[ADDRESS_422251] Dis. Nov 1995;21(5):1107- 1113.  
80. Aliberti S, Reyes LF, Faverio P, et al. Global initiative for meticilli n-resistant St aphylococcus 
aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. Sep 
[ADDRESS_422252] Infections in the 
Emergency Department Based on Loc al Antibiotic Resistance Patterns: Implic ations for 
Antimicrobial Stewardship. Infect Control Hosp Epi[INVESTIGATOR_5541]. Mar 2016;37(3):359- 360. 
82. Jacobs DM, Kuper K, Septimus E , Arafat R, Gar ey KW. Assessment of Antimicrobial 
Stewardship Activities in a Large Metropol itan Area. J Pharm Pract  2014 (Epub ahead of print).  
83. Septimus EJ, Kuper K. Clinical Challenges in Addressing Antimicrobial Resistance in the 21st 
Century. Cl Pharm and Therap 2009; 86:336- 339. 
84. Septimus E , Owens R.  Need and Potential of Antimicrobial Stewa rdship in Comm unity 
Hospi[INVESTIGATOR_600] . Clin Infec t Dis 2011;53:S8- S14. 
85. Fishman N, Patterson J, Saiman L, Srinivasan A, Trivedi KK, van Schooneveld T, Lynfield R, 
Gerding D, Septimus E, Sc hwartz D, Daum R, Eglund JA, Harrison CJ, Bradley JS, Newland J. 
Policy state ment on antimi crobial stewardship by [CONTACT_128470][INVESTIGATOR_341136] (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric 
Infectious Dis eases Society  (PI[INVESTIGATOR_16852]). Infect Control Hosp Epi[INVESTIGATOR_5541]  2012;33:322- 7. 
86. Moody J, Cosgrove SE, O lmsted R, Septimus E , Aureden K, Oriola S, Patel GW, Trivedi KK. 
Antimicrobial stewardship: a collaborative partnership between infection preventionists and 
healthcare epi[INVESTIGATOR_187543]. Infect Control Hosp Epi[INVESTIGATOR_5541]  2012;33:328 -30. 
87. Septimus EJ.  Antimicrobia l Stewardship‚ÄîQualitative and Quantitative Outcomes: The Role of 
Measurement. Curr Infect Dis Rep  2014;16:433- 438. 
88. Calderwood MS . Role of the Hospi[INVESTIGATOR_341137]. 
In: Mylonakis E, Rice L, Drusano G,  eds. Antimicr obial Stewardship: Principl es and Practices.  
2015 (in press).  
89. McKinnell J, Miller LG, Eells S, Cui E, Huang SS . A Systematic Literature Review and Meta-
analysis of Factors Associated with MRSA Colonization at Time of Hospi[INVESTIGATOR_341138].  
Infect Contr ol Hosp Epi[INVESTIGATOR_5541]  2013;34:1077- 86. 
90. Datta R, Shah A, Huang SS , Cui E, Nguyen V, Welbourne S, Quan K, Thrupp L. High nasal 
burden of methicillin- resistant Staphylococc us aureus  increases risk for invasive disease. J Clin 
Microbiol  2014;52:312- 4. 
91. Datta R, Kle inman K , Rifas -Shiman S, Pl aczek H, Lankiewicz J, Platt R , Huang SS.  
Confounding by [CONTACT_341161]- resistant 
Staphyloc occus aureus (MRSA) but not vancomycin- resistant enterococci (VRE) acquisition . 
Antibio Res ist Infect Control  2014;3:19.  
92. Pakyz AL. The utility of hospi[INVESTIGATOR_341139]. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy  
2007;27:1306 -12. 
93. Perla RJ  and Belliveau  PP. Antibiogram -derived radial decision trees: An innovative approach 
to susceptibility data display. Am J Infect Dis  2005;1:124 -7. 
94. The Center for Disease Dynamics,  Economics & Policy. Resistance Map. Available at: 
http://www.cddep.org/proje cts/resistance_map/resistance_overview_0.  Accessed on May 24, 
2015.  
95. Falcone M, Russo A, Gianella M, Cangemi R, Scarpellini MG, Bertazzoni G, Alarcon JM, Taliani 
G, Palange P, Farc omeni A, Vestri A, Bouza E, Violi F, Venditti M. Individualizing risk of 
multidrug- resistan t pathogens in community -onset pneumonia. PLoS One 2015;10:e0119528.  
96. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. Comparison of 
clinical prediction models for resistant bacteria in community -onset pneumonia. Acad Emerg  
Med 2015;22(6):[ADDRESS_422253], Coffey RM. Comorbidity measures for use with 
administrative data. Med Care 1998;36:8- 27. 
98. Healthcare Cost and Utili zation Project. Comorbidity Software, Version 3.7. Available at: 
https://www.h cup-us.ahrq.g ov/toolssoftware/comorbidit y/comorbidity.jsp#overview. Accessed 
on May 27, 2015.  
99. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes:  
mortality, length of hospi[INVESTIGATOR_4408], and health care costs. Clin Infect Dis. Jan 15 2006;[ADDRESS_422254] 
2:S82- 89. 
100. Pepin J, S aheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant 
risk factor for Clostridium difficile -associated diarrhea: a cohort study during an epi[INVESTIGATOR_341140]. Clin Infect Dis. Nov 01 2005;41(9) :[ADDRESS_422255] -spectrum 
fluoroquinolones more likely to cause Clostridium difficile- associated disease? Antimicrob 
Agents Chemother. Sep 2006;50(9):3216 -3219.  
102. FDA Drug Safety Communicat ion: FDA advi ses restricting fluoroquinolone antibiotic use for 
certain uncomplicated infections; warns about disabling side effects that can occur together . 
May 12, 2016. U.S. Food and Drug Administration. 
http://www.fda.gov/downloads/Drugs/DrugSafety/UC M500591.pdf . 
103. Kang CI, Kim SH, Park WB, et  al. Bloodstream infections due to extended- spectrum beta-
lactamase -producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and 
treatment outcome, with special emphasis on antimicrobial ther apy. Antimicro b Agents 
Chemother. Dec 2004;48(12):4574- 4581.  
104. Queen MA, Myers AL, Hall M, et al. Comparative effectiveness of empi[INVESTIGATOR_341141] -acquired pneumonia. Pediatrics. Jan 2014;133(1):e23 -29. 
105. Postma DF, van Werkhoven CH, van Elden LJ , et al. Antib iotic treatment strategies for 
community -acquired pneumonia in adults. N Engl J Med. Apr 2 2015;372(14):1312 -1323.